case_images: PMC11743589_01
case_images: Vitiligo induced by adjuvant B-Raf/mitogen-activated protein kinase-directed therapy with dabrafenib plus trametinib (A and B), presenting strong repigmentation after 6 months of topical ruxolitinib (C).
case_images: gr1.jpg
case_images: PMC11743589_01_gr1.jpg
case_images: fig1
case_images: After the scheduled end of treatment with dabrafenib plus trametinib in January 2023, the extent of vitiligo on the patient's body surface increased further, with the trunk and upper extremities as well as the patient's face becoming largely affected (Fig 1, A and B). After 3 months of twice-daily ruxolitinib (15 mg/g) administration, erythema was observed in the treated areas, followed by significant repigmentation after 6 months of ruxolitinib (Fig 1, C).